• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?

作者信息

Abdul-Ghani Muhammad

机构信息

Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX

出版信息

Diabetes Care. 2015 Mar;38(3):373-5. doi: 10.2337/dc14-2517.

DOI:10.2337/dc14-2517
PMID:25715413
Abstract
摘要

相似文献

1
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂联合二肽基肽酶-4（DPP-4）抑制剂的联合疗法在2型糖尿病管理中处于什么地位？
Diabetes Care. 2015 Mar;38(3):373-5. doi: 10.2337/dc14-2517.
2
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.达格列净或达格列净联合沙格列汀与格列美脲作为 2 型糖尿病患者二甲双胍的附加治疗的疗效和安全性。
Diabetes Obes Metab. 2018 Nov;20(11):2598-2607. doi: 10.1111/dom.13437. Epub 2018 Jul 16.
3
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.在未经控制的 2 型糖尿病患者中，与每种单一组分（加用二甲双胍）的双联疗法相比，低剂量达格列净联合沙格列汀的三联疗法。
Diabetes Obes Metab. 2019 Sep;21(9):2152-2162. doi: 10.1111/dom.13795. Epub 2019 Jun 24.
4
Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.在 52 周的时间里，达格列净联合沙格列汀加二甲双胍三联疗法在 2 型糖尿病患者中的疗效和安全性。
Diabetes Obes Metab. 2016 Nov;18(11):1134-1137. doi: 10.1111/dom.12737. Epub 2016 Aug 19.
5
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.达格列净添加至沙格列汀和二甲双胍治疗 2 型糖尿病的随机、双盲、3 期试验
Diabetes Care. 2015 Nov;38(11):2009-17. doi: 10.2337/dc15-0779. Epub 2015 Aug 5.
6
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.达格列净/沙格列汀（Qtern）用于2型糖尿病。
Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-56.
7
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.二甲双胍单药治疗血糖控制不佳的 2 型糖尿病的双联附加治疗：一项比较沙格列汀加达格列净双联附加治疗与沙格列汀或达格列净单药附加治疗加至二甲双胍的随机、双盲试验。
Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28.
8
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.沙格列汀/达格列净：用于 2 型糖尿病的治疗。
Drugs. 2017 Mar;77(3):319-330. doi: 10.1007/s40265-017-0697-1.
9
Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes.达格列净/沙格列汀固定剂量复方片剂：一种用于治疗2型糖尿病的新型钠-葡萄糖协同转运蛋白2和二肽基肽酶4组合药物。
Ann Pharmacother. 2018 Jan;52(1):78-85. doi: 10.1177/1060028017731111. Epub 2017 Sep 8.
10
Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.达格列净和沙格列汀片用于成人2型糖尿病患者。
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1303-1316. doi: 10.1080/17512433.2017.1389645. Epub 2017 Oct 18.

引用本文的文献

1
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation.使用SGLT2抑制剂和DPP4抑制剂联合治疗2型糖尿病的疗效和安全性：一项聚焦亚洲亚人群的最新系统评价和荟萃分析
Diabetes Obes Metab. 2025 Sep;27(9):5019-5031. doi: 10.1111/dom.16550. Epub 2025 Jun 24.
2
Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.评估达格列净与利格列汀联合治疗对比达格列净与维格列汀治疗二甲双胍控制不佳的2型糖尿病患者的疗效、安全性及耐受性。
Cureus. 2024 Apr 12;16(4):e58115. doi: 10.7759/cureus.58115. eCollection 2024 Apr.
3
Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.在服用钠-葡萄糖共转运蛋白 2 抑制剂的 2 型糖尿病患者中，改用与添加基于肠促胰岛素的药物。
J Am Heart Assoc. 2022 Apr 5;11(7):e023489. doi: 10.1161/JAHA.121.023489. Epub 2022 Mar 24.
4
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.一项评估西格列汀在血糖控制不佳的日本 2 型糖尿病患者中使用伊格列净的疗效和安全性的随机、安慰剂对照试验。
Diabetes Obes Metab. 2021 Jun;23(6):1342-1350. doi: 10.1111/dom.14346. Epub 2021 Feb 28.
5
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂治疗效果的预测因素及最佳联合治疗方案的考虑。
Diabetes Metab J. 2019 Apr;43(2):158-173. doi: 10.4093/dmj.2018.0057. Epub 2019 Jan 25.
6
A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.将二肽基肽酶-4抑制剂替换为钠-葡萄糖协同转运蛋白2的糖尿病患者血糖和体重变化的短期随访
Ann Saudi Med. 2018 Nov-Dec;38(6):420-426. doi: 10.5144/0256-4947.2018.420.
7
Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.钠-葡萄糖协同转运蛋白2抑制剂长期治疗的有效性：来自一家专业糖尿病中心的真实世界证据。
Diabetol Metab Syndr. 2017 Dec 1;9:96. doi: 10.1186/s13098-017-0297-y. eCollection 2017.
8
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.在二甲双胍和西格列汀治疗控制不佳的 2 型糖尿病患者中添加埃格列净的疗效和安全性：VERTIS SITA2 安慰剂对照随机研究。
Diabetes Obes Metab. 2018 Mar;20(3):530-540. doi: 10.1111/dom.13116. Epub 2017 Oct 23.
9
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.2型糖尿病管理中联合疗法的新应用——聚焦于沙格列汀和达格列净
Diabetes Metab Syndr Obes. 2017 Jul 21;10:317-332. doi: 10.2147/DMSO.S117982. eCollection 2017.
10
Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.钠-葡萄糖协同转运蛋白2抑制剂联合二肽基肽酶-4抑制剂治疗2型糖尿病：当前临床证据及理论依据综述
Drug Des Devel Ther. 2017 Mar 21;11:923-937. doi: 10.2147/DDDT.S121899. eCollection 2017.